Facebook
Twitter
LinkedIn
Forward
Managing Psoriatic Arthritis Together: A Multidisciplinary Approach to Care Between Rheumatologists and Dermatologists
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms. PsA imparts significant impact on the psychosocial, physical, and health-related quality of life (HRQoL) of the affected patient population, and data suggests this illness remains underdiagnosed or diagnosis is delayed. Systemic and biologic treatments that target the release of inflammatory cytokine signaling proteins have emerged as the gold standard for treating these chronic inflammation-mediated illnesses with high efficacy. However, hesitation in selecting these agents exists, suggesting the need for additional education regarding emerging agent safety and efficacy profiles, as well as timely diagnosis, patient preference considerations, multidisciplinary and patient-centered communication and shared decision making, and successful long-term management of PsA in the moderate to severe setting.
As such, dermatologists, rheumatologists, nurse practitioners (NPs), physician assistants (PAs), and all healthcare providers that treat patients with PsA would benefit from additional education on these topics. to appropriately promote the improvement of patient health outcomes, provider knowledge, and increased confidence. Managing PsA Together, originally presented in a live satellite symposium at the South Beach Symposium (SBS) 2022 meeting, is a 1-hour session solely centered upon collaboration between dermatology and rheumatology specialists to improve patient health outcomes, improve provider knowledge, and increase confidence.
Target Audience
This activity is designed for an audience of physicians, nurses, pharmacists, and other allied health providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology and rheumatology.
Learning Objectives
- Review new and emerging biologic drugs for treating PsA, including their safety and efficacy profiles
- Discuss effective diagnostic, treatment selection, multidisciplinary and patient-centered shared decision-making strategies to promote minimal disease activity and remission in patients PsA
- Identify the key domains of PsA and how they differ from other rheumatic/inflammatory illnesses
- Introduction: Perspectives on Dermatology and Rheumatology in Psoriatic Disease Management
- Psoriatic Arthritis Overview: Diagnosis and Treatment
- Collaborative Care: Rheumatology-Dermatology Coordination
- Key Takeaways and Pearls
Chair: Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, IN
Icahn School of Medicine at Mount Sinai Medical Center
New York City
Medical Director of DermResearch, PLLC, Physicians Skin Care, PLLC
Louisville, KY
Evan L. Siegel, MD, FACP, FACR
Medical Director, Arthritis and Rehabilitation Therapy Services
Arthritis and Rheumatism Associates, P.C.
Rockville, MD
Assistant Clinical Professor of Medicine
Georgetown University School of Medicine
Washington, DC
Disclosures
| NAME | RELATIONSHIP | COMPANY |
|---|---|---|
| Leon Kircik, MD | Investigator, Consultant, Speaker | Abbott, Acambis, Aclaris, Allergan, Almirall, Amgen, Anacor, Astellas, Asubio, Berlex, Biogen-Idec, Biolife, Biopelle, Boehringer-Ingleheim, Breckenridge Pharma, Cellceutix, Celgene, Centocor, Cipher, Coherus, Colbar, Collagenex, Combinatrix, Connetics, Coria, Dermavant, Dermik, Dermira, Dow, Dusa Pharmaceuticals, Eli Lilly, Exeltis, EOS, Ferndale, Galderma, Genentech, Glaxo-Smith Kline, HealthPoint, Idera, Intendis, Innovail, Isdin, Johnson & Johnson, 3M, Leo, L’Oreal, Maruho, Medicis, Merck, Merz, NanoBio, Novartis, Novan, Nucryst, Obagi, Onset Ther- apeutics, OrthoNeutrogena, PediaPharma, Pfizer, PharmaDerm, Promius, Puracap, QLT, Quatrix, Quinnova, Serono, SkinMedica, Stiefel, Sun Pharma, Taro, TolerRx, Triax Pharmaceuticals, UCB, Valeant, Warner & Chilcott, Xenoport, ZAGE |
| Evan Siegel, MD | Consultant | AbbVie, UCB, Janssen, BMS |
| Speaker | AbbVie, UCB, Horizon |
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse
1.0 ANCC contact hours
Pharmacist
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1 contact hours.
Commercial Support
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosures | ||
NAME | RELATIONSHIP | COMPANY |
| Leon Kircik, MD | Investigator, Consultant, Speaker | Abbott, Acambis, Aclaris, Allergan, Almirall, Amgen, Anacor, Astellas, Asubio, Berlex, Biogen-Idec, Biolife, Biopelle, Boehringer-Ingleheim, Breckenridge Pharma, Cellceutix, Celgene, Centocor, Cipher, Coherus, Colbar, Collagenex, Combinatrix, Connetics, Coria, Dermavant, Dermik, Dermira, Dow, Dusa Pharmaceuticals, Eli Lilly, Exeltis, EOS, Ferndale, Galderma, Genentech, Glaxo-Smith Kline, HealthPoint, Idera, Intendis, Innovail, Isdin, Johnson & Johnson, 3M, Leo, L’Oreal, Maruho, Medicis, Merck, Merz, NanoBio, Novartis, Novan, Nucryst, Obagi, Onset Ther- apeutics, OrthoNeutrogena, PediaPharma, Pfizer, PharmaDerm, Promius, Puracap, QLT, Quatrix, Quinnova, Serono, SkinMedica, Stiefel, Sun Pharma, Taro, TolerRx, Triax Pharmaceuticals, UCB, Valeant, Warner & Chilcott, Xenoport, ZAGE |
| Evan Siegel, MD | Consultant | AbbVie, UCB, Janssen, BMS |
| Speaker | AbbVie, UCB, Horizon | |
Dorothy Caputo, MA, BSN, RN - Senior Director of Continuing Education & Compliance | N/A | Nothing to disclose |
| Michelle Bielarski, RN | N/A | Nothing to disclose |
| Dorothy Duffy, RPh, Pharmacy Reviewer | N/A | Nothing to disclose |
LiVDerm Planners and Reviewers | N/A | Nothing to disclose |
AKH Planners and Reviewers | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.